Tarsus Pharmaceuticals (NASDAQ:TARS) Issues Earnings Results

Tarsus Pharmaceuticals (NASDAQ:TARS) issued its quarterly earnings results on Tuesday. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.08, Zacks reports. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%.

Tarsus Pharmaceuticals Trading Down 4.8 %

NASDAQ TARS opened at $45.54 on Tuesday. The firm’s 50 day moving average price is $51.75 and its two-hundred day moving average price is $42.90. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals has a twelve month low of $20.08 and a twelve month high of $57.28. The stock has a market cap of $1.74 billion, a price-to-earnings ratio of -11.95 and a beta of 1.01.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on TARS. The Goldman Sachs Group lifted their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, November 15th. Oppenheimer upped their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Guggenheim reiterated a “buy” rating on shares of Tarsus Pharmaceuticals in a research report on Monday. Finally, Barclays lifted their target price on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a report on Monday, January 27th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals has an average rating of “Buy” and an average target price of $56.00.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.